Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways

Gobe, Glenda C., Ng, Keng Lim, Small, David M., Vesey, David A., Johnson, David W., Samaratunga, Hemamali, Oliver, Kimberley, Wood, Simon, Barclay, Johanna L., Rajandram, Retnagowri, Li, Li and Morais, Christudas (2016) Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways. Biochemical and Biophysical Research Communications, 473 1: 47-53. doi:10.1016/j.bbrc.2016.03.048


Author Gobe, Glenda C.
Ng, Keng Lim
Small, David M.
Vesey, David A.
Johnson, David W.
Samaratunga, Hemamali
Oliver, Kimberley
Wood, Simon
Barclay, Johanna L.
Rajandram, Retnagowri
Li, Li
Morais, Christudas
Title Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways
Journal name Biochemical and Biophysical Research Communications   Check publisher's open access policy
ISSN 1090-2104
0006-291X
Publication date 2016-04-22
Year available 2016
Sub-type Article (original research)
DOI 10.1016/j.bbrc.2016.03.048
Open Access Status Not Open Access
Volume 473
Issue 1
Start page 47
End page 53
Total pages 7
Place of publication Philadelphia, PA, United States
Publisher Elsevier
Collection year 2017
Language eng
Abstract Apoptosis repressor with caspase recruitment domain (ARC), an endogenous inhibitor of apoptosis, is upregulated in a number of human cancers, thereby conferring drug resistance and giving a rationale for the inhibition of ARC to overcome drug resistance. Our hypothesis was that ARC would be similarly upregulated and targetable for therapy in renal cell carcinoma (RCC). Expression of ARC was assessed in 85 human RCC samples and paired non-neoplastic kidney by qPCR and immunohistochemistry, as well as in four RCC cell lines by qPCR, Western immunoblot and confocal microscopy. Contrary to expectations, ARC was significantly decreased in the majority of clear cell RCC and in three (ACHN, Caki-1 and 786-0) of the four RCC cell lines compared with the HK-2 non-cancerous human proximal tubular epithelial cell line. Inhibition of ARC with shRNA in the RCC cell line (SN12K1) that had shown increased ARC expression conferred resistance to Sunitinib, and upregulated interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF). We therefore propose that decreased ARC, particularly in clear cell RCC, confers resistance to targeted therapy through restoration of tyrosine kinase-independent alternate angiogenesis pathways. Although the results are contrary to expectations from other cancer studies, they were confirmed here with multiple analytical methods. We believe the highly heterogeneous nature of cancers like RCC predicate that expression patterns of molecules must be interpreted in relation to respective matched non-neoplastic regions. In the current study, this procedure indicated that ARC is decreased in RCC.
Keyword Angiogenesis
ARC
Drug resistance
Renal cell carcinoma
Sunitinib
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Mater Research Institute-UQ (MRI-UQ)
HERDC Pre-Audit
Admin Only - School of Medicine
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 19 Apr 2016, 00:46:49 EST by System User on behalf of Learning and Research Services (UQ Library)